64640-13-7

Basic information

• Product Name: 2-(CHLOROMETHYL)-5-PHENYL-1,3-OXAZOLE
• Synonyms: 2-Chloromethyl-5-phenyl-oxazole
• CAS NO: 64640-13-7
• Molecular Formula: C₁₀H₈ClNO
• Molecular Weight: 193.62962
• Mol File: 64640-13-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 299.5 °C at 760 mmHg
• Flash Point: 134.9 °C
• Appearance: /
• Density: 1.222 g/cm³
• Vapor Pressure: 0.00211mmHg at 25°C
• Refractive Index: 1.556
• CAS DataBase Reference: 2-(CHLOROMETHYL)-5-PHENYL-1,3-OXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(CHLOROMETHYL)-5-PHENYL-1,3-OXAZOLE(64640-13-7)
• EPA Substance Registry System: 2-(CHLOROMETHYL)-5-PHENYL-1,3-OXAZOLE(64640-13-7)

Safety Data

• Hazardous Substances Data: 64640-13-7(Hazardous Substances Data)

Usage

General Description

2-(Chloromethyl)-5-phenyl-1,3-oxazole is a chemical compound with the molecular formula C9H7ClNO. It is a heterocyclic compound containing both oxygen and nitrogen atoms in a five-membered ring structure. The chloromethyl group and phenyl group attached to the oxazole ring make it an important intermediate for the synthesis of various pharmaceutical compounds and agrochemicals. It is also used as a building block in organic synthesis for the formation of complex molecules. The compound has potential applications in the field of medicinal chemistry and is being studied for its biological activities. However, it is important to handle and use this compound with caution due to its potential reactivity and toxicity.

InChI:InChI=1/C10H8ClNO/c11-6-10-12-7-9(13-10)8-4-2-1-3-5-8/h1-5,7H,6H2

Upstream product

• 98-88-4 benzoyl chloride 
• 5468-37-1 2-aminoacetophenone hydrochloride 
• 74974-54-2 2-chloro-1,1,1-trimethoxyethane 
• 17107-25-4 5-phenyl-3H-oxazol-2-one 
• 3282-32-4 2-diazo-acetophenone 
• 107-14-2 chloroacetonitrile 
• 16722-99-9 β-azidostyrene 
• 79-11-8 chloroacetic acid 
• 67322-87-6 3-chloroacetyl-5-phenyl-3H-oxazol-2-one 
• 65385-18-4 N-(2-oxo-2-phenylethyl)chloroacetamide 
• 613-89-8 2-Aminoacetophenone 

Downstream Products

• 110703-73-6 [4-Oxo-3-(5-phenyl-oxazol-2-ylmethyl)-3,4-dihydro-phthalazin-1-yl]-acetic acid 
• 65385-19-5 1-phenyl-4-(5-phenyl-oxazol-2-ylmethyl)-piperazine 
• 143707-88-4 5-Ethyl-6-methyl-3-[(5-phenyl-oxazol-2-ylmethyl)-amino]-1H-pyridin-2-one 
• 143708-23-0 2-(iodomethyl)-5-phenyloxazole 

Relevant articles and documents

Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family

Bromodomain and extra-terminal (BET) is a promising therapeutic target for various hematologic cancers. We used the BRD4 inhibitor compound 13 as a lead compound to develop a variety of compounds, and we introduced diverse groups into the position of the compound 13 orienting toward the ZA channel. A series of compounds (14–23, 38–41, 43, 47–49) bearing triazolopyridazine motif exhibited remarkable BRD4 protein inhibitory activities. Among them, compound 39 inhibited BRD4(BD1) protein with an IC50 of 0.003 μM was superior to lead compound 13. Meanwhile, compound 39 possess activity, IC50 = 2.1 μM, in antiproliferation activity against U266 cancer cells. On the other hand, compound 39 could arrest tumor cells into the G0/G1 phase and induce apoptosis, which was consistent with its results in inhibiting cell proliferation. Biological and biochemical data suggest that BRD4 protein might be a therapeutic target and that compound 39 is an excellent lead compound for further development.

Biphenyl heterocyclic derivatives, their preparation and their use as medicaments (by machine translation)

The present invention relates to a novel biphenyl heterocyclic derivative represented by a general formula (I) and a preparation method thereof and use of a pharmaceutical composition containing the derivative for preparation of a drug for treating diabetes. The biphenyl heterocyclic derivative has extremely excellent hypoglycemic activity in vivo, and excellent in vivo safety and low liver toxicity risk of the compound having such a structure are unexpectedly found, and the novel biphenyl heterocyclic derivative may be used for preventing or treating diabetes.

Design, synthesis, and biological evaluation of N,N-disubstituted-4-arylthiazole-2-methylamine derivatives as cholesteryl ester transfer inhibitors

Cholesteryl ester transfer protein (CETP) has been identified as a potential target for cardiovascular disease (CVD) for its important role in the reverse cholesteryl transfer (RCT) process. In our previous work, compound 5 was discovered as a moderate CETP inhibitor. The replacement of the amide linker by heterocyclic aromatics and then a series of N,N-substituted-4-arylthiazole-2-methylamine derivatives were designed by utilizing a conformational restriction strategy. Thirty-six compounds were synthesized and evaluated for their CETP inhibitory activities. Structure-activity relationship studies indicate that electron donor groups substituted ring A, and electron-withdrawing groups at the 4-position of ring B were critical for potency. Among these compounds, compound 30 exhibited excellent CETP inhibitory activity (IC50 = 0.79 ± 0.02 μM) in vitro and showed an acceptable metabolic stability.